Sudden Hearing Loss Study Reaches Milestone: AudioCure Pharma Enrolls More Than Half of the Patients in AC102 Study
Berlin-based start-up AudioCure Pharma has enrolled more than 50% of the planned patients in its ongoing Phase 2 clinical trial. The aim of the study is to test the efficacy of the new compound AC102 for the treatment of sudden hearing loss. As sudden hearing loss is usually treated with non-specific corticoids that are not approved for this indication or for which there is no clear evidence of efficacy, there is an urgent need for new therapies.
This enrollment milestone is an important step in the development of AC102 and in addressing the unmet medical need for sudden hearing loss. The safety and tolerability of AC102 has already been successfully tested in healthy volunteers. “Recruitment for the trial is challenging because the compound can only be effective in the first few days after the onset of the sudden hearing loss and we can therefore only enroll patients in the study during this short window. I am therefore very pleased with this recruitment success, which underscores the high level of interest in new, more effective treatment options for patients with sudden hearing loss,” explains the coordinating investigator, Prof. Dr. Stefan Plontke of Martin-Luther-University Halle-Wittenberg.
AC102 is considered a promising alternative to corticoid therapy for sudden hearing loss, as it was able to restore hearing almost completely in an acoustic trauma model after a single application in a preclinical study1 This work also revealed the mechanism of action of AC102. Unlike the non-specific, anti-inflammatory effects of corticoids, AC102 specifically targets the sensory cells and synaptic connections in the inner ear that are responsible for hearing loss. “Our goal is to achieve a paradigm shift in the treatment of sudden hearing loss with the specific effect of AC102 and to contribute to better help sudden hearing loss patients in the future,” said Dr. Reimar Schlingensiepen, CEO of AudioCure Pharma.
The Phase 2 trial is expected to continue enrolling patients until end of 2025.
1Rommelspacher H, et al., PNAS. 2024 Apr 9;121(15)
View source version on businesswire.com: https://www.businesswire.com/news/home/20241121392544/en/
Contacts
AudioCure Pharma GmbH
Frauke Luers
Phone: +49 30 2218 397-0
E-Mail: pr@ac-clinical.com
Web: www.audiocure.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.audiocure.c
om&esheet=54156365&newsitemid=20241121392544&lan=en-US&anchor=www.audiocure.com&
index=1&md5=fae53a881da55447c16d6cdb9ffae62a
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ras Al Khaimah Named the World’s Top City for Expatriates ‘To Get Started Abroad’26.11.2024 13:30:00 CET | Press Release
Ras Al Khaimah has achieved a milestone in its journey to becoming a leading destination to live, work and explore, by securing the top position in a survey of the world’s best expat destinations, conducted by InterNations, the largest global expatriate network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241126884554/en/ Ras Al Khaimah has been named the world’s leading city for expatriates ‘to get started abroad’, according to the 2024 Expat Insider report by @internationsorg, where Ras Al Khaimah ranked first among 53 cities. Find out more about RAK @HeartofRAK. (Photo: AETOSWire) The Emirate secured number one spot out of 53 cities in the Expat Essentials Index, conducted by InterNations as part of its 2024 Expat Insider report. The Index is based on four categories: Admin (how easy it is to get a visa, deal with local bureaucracy, open a bank account); Housing (affordability of housing, ease of finding accommodation)
Marelli Extends Relationship with Wipro for Continued Evolution of IT Infrastructure26.11.2024 12:51:00 CET | Press Release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, has today announced the extension of its work with Marelli, a global leader in automotive solutions, for an additional four years. As part of this engagement, Wipro FullStride Cloud will migrate Marelli’s Milan Data Centre and all their local server rooms to the Cloud to centralize their operations and provide a more agile and stable ecosystem. This transition to a more flexible and advanced cloud environment will empower Marelli to respond quickly to market changes, enable continuous innovation across their business, and strengthen their competitive edge. Ultimately, the project will help reduce the time-to-market for Marelli's products and services, creating long-term value for all stakeholders, continuing to advance Marelli's journey towards modernization and growth. “We are excited to begin a new chapter in our strategic partnership with our trusted partner, Marelli. Our wide-r
Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-1432326.11.2024 12:00:00 CET | Press Release
We are excited to share our latest development status. Similar to its position in the United States, we are pleased to announce that Afatinib, which is being treated with DFP-14323 in our ongoing Phase III clinical trial, has been approved by the Japanese Lung Cancer Society in its “Lung Cancer Treatment Guidelines 2024” (issued on October 20, 2024) as a first-line treatment for EGFR mutation-positive (uncommon mutation) non-small cell lung cancer (NSCLC), with a stronger recommendation than Osimertinib. The development of DFP-14323 is being conducted in patients (stage III/IV) with epidermal growth factor receptor (EGFR) mutation-positive uncommon mutation NSCLC in a Phase III clinical trial (superiority study) comparing DFP-14323 in combination with Afatinib (20 mg/day) and Afatinib (40 mg/day) alone. The strongly recommended treatment with afatinib as first-line therapy must accelerate the enrollment of NSCLC patients through this trial. The study is being conducted at 30 core hospi
Netmore Group and Vantage Towers Partner to Expand Nationwide LoRaWAN ® Connectivity in Portugal26.11.2024 12:00:00 CET | Press Release
Netmore Group, a leading global LoRaWAN network operator, and Vantage Towers, a major provider of telecommunications tower infrastructure to the European market, today announced a strategic partnership to deliver national LoRaWAN connectivity across Portugal to support the digital transformation and sustainability initiatives of utilities, municipalities, and other organizations. Like many regions across the globe, addressing water scarcity is a leading initiative across Portugal and a leading use case for low power wide area network (LPWAN) sensing technology. Record droughts this year have forced significant water restrictions and strained the operations of water utilities throughout the country, particularly in the southernmost Algarve region, where reservoirs are only 20% full on average. Additionally, Portugal loses nearly a third of its water through leaks, theft or illicit use, according to ERSAR, the country’s national water supply and sanitation agency. To combat these challen
Blackstone Credit & Insurance Announces $1 Billion Infrastructure Loan Portfolio Purchase From Santander26.11.2024 11:30:00 CET | Press Release
Blackstone and Santander Corporate & Investment Banking today announced an agreement under which funds managed by Blackstone Credit & Insurance (“BXCI”) will acquire interests in a $1 billion portfolio of high-quality infrastructure loans from Santander. The portfolio comprises loans that finance assets located largely in Western Europe and the US across the digital infrastructure, utility scale renewable, energy efficiency and transportation sectors. Robert Horn, Global Head of Infrastructure & Asset Based Credit at BXCI, said: “This transaction is consistent with our approach to working with leading financial institutions on large-scale, long-term, efficient solutions that support their capital goals.” Marcel Patiño, Global Head of Private Debt Mobilization at Santander CIB, said: “We are delighted to partner with Blackstone on this strategic transaction as we look to streamline our balance sheet while supporting further growth by Santander as a leading advisor and arranger in the St
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom